As war rages and Trump looms, a recent Denmark election featured little mention of the ailing $164 billion drugmaker Novo Nordisk. In this Viewsroom podcast, Breakingviews columnists discuss the future of weight‑loss pills and Novo’s place in it

As war rages and Trump looms, a recent Denmark election featured little mention of the ailing $164 billion drugmaker Novo Nordisk. In this Viewsroom podcast, Breakingviews columnists discuss the future of weight‑loss pills and Novo’s place in it

Go to News Site